Blueprint Medicines Q4 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
88,140€
-3,69%
Echtzeit-Aktienkurs Blueprint Medicines Corp
Bid:
Ask:
Nachrichten zur Blueprint Medicines Corp Aktie
XFRA : 2L9: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
Form 8-K Blueprint Medicines Corp For: Feb 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines BLU-222 Study on FDA Partial Hold >BPMC
Blueprint Medicines BLU-222 Study on FDA Partial Hold >BPMC...…
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Can Blueprint Medicines (BPMC) Climb 61.38% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.4% in Blueprint Medicines (BPMC).…
Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocytosis >BPMC
Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocytosis >BPMC...…
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass., Jan. 23, 2023…
Form 8-K Blueprint Medicines Corp For: Jan 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D.,…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…